Tarsus Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:TARS) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 376.3 M376.99 M500.75 M494.99 M534.56 M562.16 M Total liabilities 138.82 M152.46 M158.29 M162.38 M199.48 M218.73 M Total equity 237.48 M224.53 M342.46 M332.61 M335.08 M343.43 M Total liabilities & shareholders' equities 376.3 M376.99 M500.75 M494.99 M534.56 M562.16 M Total debt —————— Net debt ——————

Notizie

Miners Barrick, Pan American Leads 10 Hot Growth Stocks Onto The IBD 50, Other Premium Lists

These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.

ASML, With Unique AI Tech, Leads 8 Hot Growth Stocks Joining IBD's Top Screens

Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders

AMD, IBM among market cap stock movers on Tuesday

Gli EPS di Tarsus hanno mancato le aspettative per 0,12$, il fatturato supera le previsioni

Tarsus earnings missed by $0.12, revenue topped estimates

Tarsus Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:TARS) 2026-02-23

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates

Earnings call transcript: Tarsus Pharmaceuticals Q4 2025 sees robust growth

Tarsus affronta il test degli utili mentre le perdite si riducono e i ricavi aumentano

Tarsus faces earnings test as losses narrow, revenue surges